Anti-Human CD37 Recombinant Antibody (Lilotomab) (CAT#: TAB-467CQ)

Recombinant monoclonal antibody to CD37. Lilotomab is a mouse monoclonal antibody that can be potentially used in the treatment of Non-Hodgkin's lymphoma (NHL).

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Toxicity of Lilotomab.

Figure 1 Toxicity of Lilotomab.

Lack of correlation between RM dose derived by surrogate method and reduction in thrombocyte (A) and neutrophil (B) counts demonstrates that this non–imaging-based method is unfit to predict marrow toxicity for 177Lu-lilotomab satetraxetan therapy.

Blakkisrud, J., Løndalen, A., Dahle, J., Turner, S., Holte, H., Kolstad, A., & Stokke, C. (2017). Red marrow–absorbed dose for non-hodgkin lymphoma patients treated with 177lu-lilotomab satetraxetan, a novel anti-cd37 antibody–radionuclide conjugate. Journal of Nuclear Medicine, 58(1), 55-61.

Figure 2 DNA content and DNA damage in U-2932 and RIVA cells after treatment with 177Lu-lilotomab satetraxetan.

Figure 2 DNA content and DNA damage in U-2932 and RIVA cells after treatment with 177Lu-lilotomab satetraxetan.

Cells were treated with indicated doses of 177Lu-lilotomab satetraxetan [600 MBq/mg] for 18 hours, washed and fixated. DNA content (FxCycleFarRed) and DNA damage (anti-P-g-H2AX) were assessed by flow cytometry.

Rødland, G. E., Melhus, K., Dahle, J., Syljuåsen, R., & Patzke, S. (2018). Cell Cycle Kinase Inhibitors Potentiate the Effect of 177lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines.

Figure 3 ADCC induction by (A) obinutuzumab and (B) rituximab in Raji 2R cells relative to untreated Raji cells of corresponding mAb exposure.

Figure 3 ADCC induction by (A) obinutuzumab and (B) rituximab in Raji 2R cells relative to untreated Raji cells of corresponding mAb exposure.

Statistical significance by 2-tailed t-test where *** p< 0.001 and ** p< 0.01 (N=3).

Marion M. Malenge, Sebastian Patzke, Anne Hansen Ree,… & and Ada H. V. Repetto-Llamazares. 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab and obinutuzumab in non-Hodgkin’s lymphoma.

Figure 4 177Lu-lilotomab satetraxetan and the increase was dependent on the concentration of 177Lu-lilotomab satetraxetan.

Figure 4 177Lu-lilotomab satetraxetan and the increase was dependent on the concentration of 177Lu-lilotomab satetraxetan.

Rituximab binding presented as mean ± SD of median fluorescence intensity (MFI) plotted against escalating concentrations of mAbs at 3 and 6 days in Raji 2R and in Raji cells (N=3).

Marion M. Malenge, Sebastian Patzke, Anne Hansen Ree,… & and Ada H. V. Repetto-Llamazares. 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab and obinutuzumab in non-Hodgkin’s lymphoma.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Mouse
  • Type
  • IgG1, κ
  • Specificity
  • Human CD37
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IHC, FC, IP, IF, FuncS
  • Conjugate
  • Unconjugated
  • Trade name
  • Betalutin
  • CAS
  • 1453362-55-4
  • Generic Name
  • Lilotomab
  • UNII
  • 58I6YNR7BV
  • Related Disease
  • Non-Hodgkin's lymphoma (NHL)

Product Property

  • Purity
  • > 95% as determined by SDS-PAGE
  • Storage
  • Store at -20°C for long-term storage. Avoid freeze/thaw cycles.

Applications

  • Application Notes
  • The CD37 antibody has been reported in applications of Cyt, FC, ADCC, IF.

Target

  • Alternative Names
  • CD37; CD37 molecule; GP52-40; TSPAN26; leukocyte antigen CD37; tspan-26; tetraspanin-26; leukocyte surface antigen CD37; cell differentiation antigen 37;

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Lilotomab"

Afuco™ Anti-CD37 ADCC Recombinant Antibody (Lilotomab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD37. Lilotomab is a mouse monoclonal antibody that can be potentially used in the treatment of Non-Hodgkin's lymphoma (NHL).

See other products for "CD37"

Humanized Antibody

CAT Product Name Application Type
TAB-904 Anti-Human CD37 Recombinant Antibody (Otlertuzumab) ELISA, IP, FC, FuncS, Neut, IF, ICC VH - V-kappa - CH2 - CH3

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-467CQ Afuco™ Anti-CD37 ADCC Recombinant Antibody (Lilotomab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for TAB-467CQ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare